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Patient Characteristics by Post-Cy Group
Characteristics Post-Transplant
Cyclophosphamide
P- value*
Yes No
n ¼ 21 % n ¼ 35 %
Age group (years)
0.1-9.9 17 81 26 74 .75
10.0-19 4 19 9 26
F. donor / M receptor 6 29 8 23 .90
Double cord 3 14 3 9 .66
Diagnoses
Acute leukemias 12 57 17 49
Abstracts / Biol Blood Marrow Transplant 19 (2013) S150eS166 S165matched sibling bone marrow transplantation results in
approximately 85% event free survival in high-risk patients
with Sickle Cell Disease (SCD) (Walters, NEJM, 2006).
However, this approach is limited by 5-10% transplant-
related mortality, 5-10% primary graft failure and the late
effects of Bu/CY. Alternate approaches include reduced
toxicity but more immunosuppressive conditioning and the
use of sibling cord blood (Geyer/Cairo, BJH, 2011 and Freed/
Cairo, BMT, 2012).
Objective: To determine the safety, donor chimerism and
long term organ function associated with Bu 12.8-16 mg/kg,
ﬂudarabine180 mg/m2 and alemtuzumab 54 mg/m2 (BFA)
reduced toxicity conditioning (RTC) prior to HLA-matched
sibling donor transplantation in pediatric recipients with
high risk SCD.
Methods: Patients 21 years of age with HbSS, HbSC, HbSb+
or HbSb0 were eligible if highly symptomatic (such as 2
vaso-occlusive crises per year requiring narcotics, acute chest
syndrome, stroke, retinopathy, splenic sequestration) and
with an HLA-matched sibling donor. Conditioning consisted
of busulfan (4mg/kg x 4d < 4 yrs and 12.8mg/ kg x 4d > 4
yrs), ﬂudarabine (30mg/m2 x 6d), and alemtuzumab (2mg/
m2 x 1d, 6mg/m2 x 2d, and 20mg/m2x 2d) as we have
described (Styczynski/Cairo,BMT,2011). All received tacroli-
mus and MMF as GVHD prophylaxis as we have described
(Bhatia/Cairo, BBMT, 2010).
Results: 12 patients (11M:1F), median age 12 (2-19) with
symptomatic SCD underwent sibling BM (n¼10) or CB (n¼2)
Allogeneic Stem Cell Transplantation (AlloSCT). Median
follow-up was 33 months. Median time to neutrophil and
platelet engraftment for recipients of sibling BM and CBwere
16 days (13-18), 18.5 days (9-43) and 39.5 days (38-41) and
74 days (73-75), respectively. The probability of grade II-IV
and grade III-IV aGVHD were 16.7% and 8.3%. No patients
developed cGVHD. Patients achieved mean whole-blood
donor chimerism of 85, 94, 93, 93, 89 and 93% and mean
erythroid (CD71) donor chimerism of 89, 89, 93, 90, 86, and
94% at days 30, 60, 100, 180, 365 and 730 post-transplant,
respectively. The Kaplan-Meier probability of OS and EFS was
100% (CI95: 73.5-100%). Neurological, pulmonary, vascular,
and splenic function were stable to improved at 2 years.
Conclusions: BFA (RTC) and HLA-matched sibling bone
marrow and cord blood AlloSCT in pediatric recipients
results in excellent EFS, long term donor chimerism, and
stable/improved organ function.SAA 3 14 8 23 .58
Others 6 29 10 29
RIC 7 33 16 46 .41
TBI 12 57 22 63 .78
ATG or Alemtuzumb 6 29 17 49 .17
HLA match (n¼52)
6/6 1 5 6 19
5/6 9 50 11 34 .31
4/6 10 45 15 47
Receptor CMV (+) 21 100 30 86 .14
CMV viremia 13 62 19 54 .78
Invasive mycosis 4 19 6 17 .99101
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Post-transplant Cyclophosphamide (Post-Cy) has demon-
strated to decrease the occurrence of aGVHD inpreclinical and
haploidentical studies. Nevertheless, Post-Cy increases time to
neutrophil recovery, an issue that is of utmost importance for
UCB transplant related mortality (TRM). We postulated that
despite UCB lower cellular doses, the use of Post-Cy decreases
graft vs host and host vs graft reactions, enhancing engraft-
ment, and improving clinical outcomes. So we explore the
feasibility of using Post-Cy in the setting of UCB trans-
plantation in children. In June/2010, our group decided to
include post-Cy for UCB transplantation. A single 50 mg/kg/
dose of Cywas addedonday +3. CSA andMMFwas started day+4, as well as G-CSF. Post-Cy was used both in RIC and mye-
loablative transplants. Rabbit ATG or Alemtuzumab was used
only for RIC transplants. The group that received Cy-Post (21
cases) was compared with our previous UCB transplantation
cases (35 cases) where Post-Cy was not used. Multivariate
logistic regression models were used to evaluate the inde-
pendence of the relationship between Cy-Post and aGvHD, of
other covariates such as, age, gender, RIC, HLA match, CMV
receptor status, pre-freezing TNC and CD34. Attached table
compares characteristics ofpatientswith andwithout Post-Cy.
No signiﬁcant differenceswere identiﬁed among the 2 groups.
The groupswith andwithout Post-Cywere infusedwith 7.1 vs
6.4x107 TNC/kg, and 2.84 vs 2.81x105 CD34+cells/kg, respec-
tively. 100-day (25% vs 26%) and 1-year (25% vs 31%) TRM and
overall survival (60% vs 57%) were not different among the
groups. Median time to neutrophil and platelet engraftment
with andwithout Post-Cywas24vs 16days (P< .01), and43vs
35 days (P¼0.02), respectively. Forty-nine (87.5%) patients
were evaluable for aGvHD, 49% were classiﬁed as grades II-IV.
In the group with Post-Cy grades II-IV aGvHD was 32%
comparedwith 68% in the groupwithout Post-Cy. ORwas 0.31
(95%CI:0.1, 1.0), and adjusted OR was 0.16 (95%CI: 0.03, 0.78),
P¼ .02. Nodocumented cases of grade IV aGvHD in thePost-Cy
group. In conclusion, we found an important effect of Post-Cy
over the occurrence of aGVHD, independently of HLA match,
and of other relevant variables. Neither, we ﬁnd an effect over
earlyTRM,and isuncertain its impactover long termmortality.
We hypothesize that usage of Post-Cy in UCB transplantation
in children, can allow the use of UCB units with greater HLA
mismatch, and thus, increasing the potential pool of grafts
available for transplantation. This couldbeespeciallyuseful for
ethnic minorities.* Fisher’s exact two sided test.102
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